Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA

Company Overview - Stoke Therapeutics is a biotechnology company focused on restoring protein expression through RNA medicine, with its lead investigational medicine, zorevunersen, aimed at treating Dravet syndrome, a severe neurodevelopmental disorder characterized by recurrent seizures and cognitive impairments [3][9] - The company was founded in 2015 and has advanced zorevunersen from early clinical testing to late-stage development, preparing for commercialization in the United States [4][9] New Headquarters - Stoke Therapeutics has secured a long-term lease for a new 98,500 square-foot headquarters at 245 Fifth Avenue in Waltham, Massachusetts, which is one of the largest leases in the Greater Boston life sciences sector over the past year [1][2] - The relocation is set to occur when the current lease in Bedford, Massachusetts ends in late 2026 [1] Growth and Research Expansion - The new headquarters will support Stoke's growth trajectory as it prepares to commercialize zorevunersen and expand research efforts for additional medicines targeting severe diseases [5] - The Waltham area is recognized as a resilient hub for life sciences, providing operational efficiency and access to top talent, which aligns with Stoke's strategic goals [5] Infrastructure and Sustainability - The new property is LEED Gold and WiredScore Platinum certified, emphasizing sustainability and connectivity, with modern infrastructure designed for lab-ready use [5] Market Context - Despite a moderation in the national life sciences market, the Greater Boston area, particularly Waltham and the Route 128 corridor, continues to demonstrate strength and resilience in supporting the biotech industry [5]